Literature DB >> 33677756

A novel transcript variant of human G-protein coupled estrogen receptor.

Uttariya Pal1, Mohan C Manjegowda1, Anil Mukund Limaye2.   

Abstract

The G-protein coupled estrogen receptor (GPER) mediates short-term non-genomic effects of estrogen in diverse cell types and tissues. According to the NCBI nucleotide database, three variants of GPER are known. They are NM_001505.2 (GPER-v2), NM_001039966.1 (GPER-v3), and NM_001098201.1 (GPER-v4). Investigations on GPER expression are key to understand its physiological and pathological roles. However, most studies on GPER mRNA expression have considered total GPER mRNA expression regardless of the individual variants. The present study is motivated by a novel transcript observed in the UCSC Genome Browser (uc010ksd.1), which is annotated as GPER. The novel variant is similar to the known transcript variants of GPER in terms of the protein-coding sequence and the 3'UTR. However, it has a unique 5'UTR, which distinguishes it from other GPER variants. Using primers specific for uc010ksd.1, we have performed RT-PCR to show that the novel GPER transcript (hereafter referred to as GPER-v5) is expressed in human cancer cell lines, such as MCF-7, SW-620, COLO-205, and HT-29. Preliminary evidences indicate that GPER-v5 is a novel GPER mRNA variant. The expression of GPER-v5 in primary cells and tissues should be investigated before probing into its role and relevance in physiological and pathological conditions.

Entities:  

Keywords:  Cell lines; GPER; RT-PCR; mRNA variant

Mesh:

Substances:

Year:  2021        PMID: 33677756     DOI: 10.1007/s11033-021-06242-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  15 in total

1.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.

Authors:  E J Filardo; J A Quinn; K I Bland; A R Frackelton
Journal:  Mol Endocrinol       Date:  2000-10

2.  Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.

Authors:  P Thomas; Y Pang; E J Filardo; J Dong
Journal:  Endocrinology       Date:  2004-11-11       Impact factor: 4.736

3.  Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.

Authors:  Edward J Filardo; Jeffrey A Quinn; A Raymond Frackelton; Kirby I Bland
Journal:  Mol Endocrinol       Date:  2002-01

Review 4.  Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-05-13       Impact factor: 3.072

5.  G protein-coupled receptor 30 (GPR30) forms a plasma membrane complex with membrane-associated guanylate kinases (MAGUKs) and protein kinase A-anchoring protein 5 (AKAP5) that constitutively inhibits cAMP production.

Authors:  Stefan Broselid; Kelly A Berg; Teresa A Chavera; Robin Kahn; William P Clarke; Björn Olde; L M Fredrik Leeb-Lundberg
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

Review 6.  The unfolding stories of GPR30, a new membrane-bound estrogen receptor.

Authors:  Marcello Maggiolini; Didier Picard
Journal:  J Endocrinol       Date:  2009-09-18       Impact factor: 4.286

7.  Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer.

Authors:  C Carmeci; D A Thompson; H Z Ring; U Francke; R J Weigel
Journal:  Genomics       Date:  1997-11-01       Impact factor: 5.736

8.  Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Authors:  Deo Prakash Pandey; Rosamaria Lappano; Lidia Albanito; Antonio Madeo; Marcello Maggiolini; Didier Picard
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

9.  Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

Authors:  Romana Koppensteiner; Eleftherios P Samartzis; Aurelia Noske; Adriana von Teichman; Ioannis Dedes; Myriam Gwerder; Patrick Imesch; Kristian Ikenberg; Holger Moch; Daniel Fink; Manuel Stucki; Konstantin J Dedes
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.